Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissues
Open Access
- 24 October 2003
- journal article
- research article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 50 (5), 944-954
- https://doi.org/10.1002/mrm.10614
Abstract
Proton high-resolution magic angle spinning (1H HR-MAS) NMR spectroscopy and quantitative histopathology were performed on the same 54 MRI/3D-MRSI-targeted postsurgical prostate tissue samples. Presurgical MRI/3D-MRSI targeted healthy and malignant prostate tissues with an accuracy of 81%. Even in the presence of substantial tissue heterogeneity, distinct 1H HR-MAS spectral patterns were observed for different benign tissue types and prostate cancer. Specifically, healthy glandular tissue was discriminated from prostate cancer based on significantly higher levels of citrate (P = 0.04) and polyamines (P = 0.01), and lower (P = 0.02) levels of the choline-containing compounds choline, phosphocholine (PC), and glycerophosphocholine (GPC). Predominantly stromal tissue lacked both citrate and polyamines, but demonstrated significantly (P = 0.01) lower levels of choline compounds than cancer. In addition, taurine, myo-inositol, and scyllo-inositol were all higher in prostate cancer vs. healthy glandular and stromal tissues. Among cancer samples, larger increases in choline, and decreases in citrate and polyamines (P = 0.05) were observed with more aggressive cancers, and a MIB-1 labeling index correlated (r = 0.62, P = 0.01) with elevated choline. The elucidation of spectral patterns associated with mixtures of different prostate tissue types and cancer grades, and the inclusion of new metabolic markers for prostate cancer may significantly improve the clinical interpretation of in vivo prostate MRSI data. Magn Reson Med 50:944–954, 2003.Keywords
This publication has 33 references indexed in Scilit:
- Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancerJournal of Magnetic Resonance Imaging, 2002
- Treatment of prostate cancerJournal of Clinical Pharmacy & Therapeutics, 1999
- Improved water and lipid suppression for 3D PRESS CSI using rf band selective inversion with gradient dephasing (basing)Magnetic Resonance in Medicine, 1997
- Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin‐echo pulse sequenceMagnetic Resonance in Medicine, 1997
- In vitro high resolution 1h‐spectroscopy of the human prostate: Benign prostatic hyperplasia, normal peripheral zone and adenocarcinomaMagnetic Resonance in Medicine, 1993
- Identification ofscyllo-inositol in proton NMR spectra of human brainin vivoNMR in Biomedicine, 1993
- Phosphorus metabolite characterization of human prostatic adenocarcinoma in a nude mouse model by31P magnetic resonance spectroscopy and high pressure liquid chromatographyNMR in Biomedicine, 1992
- Differentiation of human prostate cancer from benign hypertrophy byin vitro1H NMRMagnetic Resonance in Medicine, 1992
- MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopyJournal of Magnetic Resonance (1969), 1985
- Citric Acid in Human Prostatic Secretion and Metastasizing Cancer of Prostate GlandBMJ, 1962